There is wide variability in the response of individuals to standard doses of antipsychotic drugs. It has been suggested that this may be partly explained by differences in the cytochrome P450 (CYP450) enzyme system responsible for metabolizing the drugs. We conducted a systematic review and metaanalyses to consider whether testing for CYP450 single nucleotide polymorphisms in adults starting antipsychotic treatment for schizophrenia predicts and leads to improvements in clinical outcomes. High analytic validity in terms of sensitivity and specificity was seen in studies reporting P450 testing. However, there was limited evidence of the role of CYP2D6 polymorphisms in antipsychotic efficacy, although there was an association between CYP2D6 genotype and extrapyramidal adverse effects. No studies reported on the prospective use of CYP2D6 genotyping tests in clinical practice. In conclusion, evidence of clinical validity and utility of CYP2D6 testing in patients being prescribed antipsychotics is lacking, and thus, routine pharmacogenetic testing prior to antipsychotic prescription cannot be supported at present. Further research is required to improve the evidence base and to generate data on clinical validity and clinical utility.
Introduction
CYP2D6 is perhaps the most intensively studied gene in the area of pharmacogenetics. It is an important enzyme responsible for the metabolism of 25% of drugs, including antipsychotics and antidepressants. It is polymorphically expressed, being absent in 6-10% of Caucasians and 1% of Asians, 1 who are known as poor metabolizers (PMs). Patients with two wild-type (wt) or functional alleles are referred to as extensive metabolizers (EMs). Individuals homozygous or heterozygous for reduced function alleles are commonly considered intermediate metabolizers (as are those who are heterozygous for non-functional alleles). About 1-2% of Caucasians and over 25% of Ethopians are ultra-rapid metabolizers (UMs), 2 individuals with multiple copies of functional alleles and who are considered at increased risk of non-response to drugs. 3 The ultimate aim of pharmacogenetic research is to introduce pre-treatment testing that would allow personalization of therapies in terms of drug choice or drug dose, and thereby improve clinical outcomes. 4 However, there is also increasing realization that testing will need to adhere to standards. To this end, the Analytic validity, Clinical validity, Clinical utility and Ethical, legal and social implications model has been developed to structure the assessment of pharmacogenetic diagnostic tests. 5 Analytic validity assesses the test's accuracy (sensitivity and specificity) in predicting a genotype and also includes issues of quality control and robustness of the assessment. The test's clinical validity defines its ability to predict, based on the genotype, not only a person's phenotype (that is metabolizer status) but more importantly drug response such as efficacy and adverse effects. Clinical utility refers to the ability to use the information from analytic and clinical validity to influence clinical practice, specifically to alter prescribing decisions, and improve clinical outcomes. Ethical, legal and social implications of testing include issues such as delays in treatment that may occur in awaiting pharmacogenetic test results or denying patients the prescription of a certain drug based on the test results.
There is wide variability in the response of individuals to standard doses of antipsychotic drug therapy, with some patients either failing to achieve the intended therapeutic effect or experiencing adverse drug reactions (ADRs), or sometimes both. Part of this variability may be explained by differences in drug metabolism between different individuals. 6, 7 Most antipsychotic agents are highly lipophilic and undergo extensive metabolism, in particular by the cytochrome P450 (CYP450) enzymes CYP2D6, CYP1A2 and CYP3A4 8 ( Table 1) . Most of the work to date has focused on the role of CYP2D6 polymorphisms in determining variability in drug levels and thereby in the response to antipsychotics. Two previous reviews 9 , 10 have reported significant relationships between CYP2D6 and steady-state concentrations for typical antipsychotics and risperidone, and suggested that PMs may be more prone to parkinsonism, but not for other outcomes. A more recent metaanalysis 11 has reported a link between non-functional alleles and tardive dyskinesia (TD), but this was not seen at the genotype level ( Supplementary Figures 1-8) .
Despite the extensive amount of work with CYP2D6 and antipsychotics, and the contradictory findings to date, phenotyping or genotyping for CYP2D6 is not routinely used in patients started on antipsychotics. An analogous situation has also been observed with antidepressants such as selective serotonin reuptake inhibitors (SSRIs), which are also extensively metabolized by CYP2D6 and show wide inter-individual variability in response. A recent systematic review on the role of CYP2D6 polymorphisms in SSRI metabolism and response 12 concluded that there was inadequate information to warrant pre-prescription genotyping for CYP2D6.
In this paper, we have undertaken a systematic review and meta-analyses to assess whether testing for genetic variation in CYP2D6 and other relevant P450 genes in adults prescribed antipsychotics produces accurate results (analytic validity), whether such testing predicts clinical outcomes (clinical validity) and whether it therefore improves clinical outcomes in practice (clinical utility). Our aim was to assess the quality of evidence base that currently exists in relation to P450 polymorphisms and antipsychotic response, which hopefully provides insight into the areas that need further study.
Materials and methods

Literature search
The review comprised three components: (1) analytic validity, (2) Ziprasidone at stage one were obtained and assessed independently by two reviewers for inclusion and study quality. Data relating to study design, methodology and findings were independently extracted and checked by the same reviewers using a pre-tested data extraction form. Authors were contacted for the provision of any missing data.
Inclusion criteria and outcome measures
For analytic validity, any study design comparing one test with another (the reference method, which could be any type of assay) was eligible for inclusion, whereas for clinical validity any study design except single case studies could be included. Any study design was eligible for inclusion for evidence of clinical utility. For all parts of the review, inclusion criteria included both conference abstracts and full papers.
The study population in analytic validity studies included healthy or unhealthy adults genotyped for any CYP450 single nucleotide polymorphisms, deletions or duplications. For clinical validity, the study population included adults with schizophrenia receiving treatment with antipsychotics and genotyped for CYP450 and for clinical utility, adults with any disease treated with antipsychotics and undertaking a pharmacogenetic test for CYP450 were included.
Outcome measures for analytic validity included any reporting on the accuracy of the test. For clinical validity, specific pharmacokinetic outcomes (bioavailability area under curve (AUC), half-life (t 1/2 ) or oral clearance), any outcome-measuring efficacy or any outcome reporting on adverse effects were included. A broad approach was taken to inclusion criteria for clinical utility outcomes including: the use of CYP450 genotyping to prospectively predict clinical outcomes (outcomes include those addressed by clinical validity); the use of CYP450 genotyping to modify clinical management (for example changing doses based on genotype tests); examples of the use of CYP450 genotyping in medical, personal and public health decision making; and harms associated with CYP450 genotyping.
Quality assessment
As no consensus standardized method for the quality assessment of analytic validity studies currently exists, no formal quality assessment was attempted for this part of the review although general issues relating to both study design and conduct of genetic association studies in particular were considered when reviewing the data. For clinical validity, the general study design and conduct of studies were considered based on accepted criteria 13 and a tool based on elements of a checklist developed to assess the methodological quality of pharmacogenetic studies 14 was used to assess specific issues considered important in terms of the reliability of such studies. No quality assessment was possible for clinical utility due to the lack of studies.
Statistical analysis
Where analytic validity studies did not report sensitivity and specificity data, attempts were made to calculate these values in each study.
For clinical validity, meta-analyses were undertaken following the guidelines set out in the HuGENet handbook 14 for undertaking meta-analyses of genetic association studies. Review Manager 4.2 software (RevMan) was used. Forest plots were prepared with binary outcomes compared in terms of odds ratios (ORs) and continuous outcomes compared in terms of difference in means. An assessment of heterogeneity between studies was made both by visually inspecting the forest plots and by calculating the I 2 statistic, 15 which measures the proportion of variation across studies that is due to genuine differences rather than due to random error. If heterogeneity was detected, summary effects were estimated using a random-effects approach; otherwise, a fixed effects approach was taken. Where studies differed in terms of study design and/or the ethnicity of included patients, separate effect estimates (sensitivity analyses) were calculated for each study type and ethnic group where possible.
For the purposes of the meta-analyses, alleles were considered to be either functional (wt) or mutant (mut) and grouped into any one of the following genotype groups: wt/wt, wt/mut or mut/mut. Given the large variations in the frequencies of the most common PM alleles (*3, *4, *5 and *6) and the *10 allele between Caucasian and Asian populations, sensitivity analyses were undertaken to account for these differences. As the *2 allele may be associated with normal function, patients with the *1/*2 genotype were classified as wt/wt. In studies where UMs were detected, patients were also classified as wt/wt as such individuals have at least two wt alleles and as many of the other studies did not use tests that were able to identify multiple copies (42) of wt alleles. This approach is consistent with that used by Patsopoulos et al. 11 and is pragmatic given the small number of UM patients in studies published to date, and obviates the need to ignore them from the analysis. No statistical analysis was possible for clinical utility due to the lack of studies.
Results
Analytic validity
Forty-one out of 2841 papers met the inclusion criteria for analytic validity. As three papers considered multiple CYP450 genes, there were a total of 46 studies examining single nucleotide polymorphisms within 11 different CYP450 genes, most commonly CYP2D6 (21/46 studies).
For all genes, real-time polymerase chain reaction was the most frequent genotyping method (13/46 studies) although for CYP2D6, the most common method was a microarray particularly the Roche AmpliChip or its predecessor, the GeneChip (6/21). The most frequent method used as a reference method for any CYP450 was polymerase chain reaction followed by restriction fragment length polymorphism (19/46) . DNA sequencing is commonly considered the gold standard for identifying genotypes; in the 13 studies where this was used, this was most commonly used to test only a subset of samples.
CYP450 testing for prescribing antipsychotics in adults with schizophrenia
N Fleeman et al
Studies varied in size from 40 subjects genotyped in the smallest study 56 to 428 in the largest, 30 although the number of samples being compared by the reference method varied from 6 38 to 1400 samples. 31 The majority of studies were conducted in Europe (22/46); half (23/46) reported the ethnic origin of their subjects that was usually either solely or mainly Caucasian in 14 studies.
The four aspects of analytic validity were reported in varying quality: 22/46 studies presented sensitivity data that was typically 100%; with the exception of one CYP2D6 study, 22 specificity was always 100%. Assay robustness and quality control were rarely discussed.
Clinical validity
Forty-seven out of 2151 papers reported data on clinical validity. The majority studied more than one CYP450 gene, resulting in a total of 51 studies covering six different genes (CYP2D6, CYP1A2, CYP17, CYP3A4 and CYP3A5). The most commonly studied genes were CYP2D6 (38/51 studies) and CYP1A2 (9/51). All studies reported sample size, ranging from 9 to 309 (mean 101, median 92). Compared with the sample sizes required to provide sufficient power to detect an effect of the size seen with most genetic single nucleotide polymorphisms, these studies were all small. For example, where 20% of a study population were expected to carry the mutant allele, to be adequately powered to detect a significant difference between groups, the sample size would need to be 2585 where the OR ¼ 1.5 or 755 where the OR ¼ 2.0. 104 None of the studies explained how the sample size had been chosen or stated the a priori power for detecting effect sizes of varying degrees.
Generally, studies presented adequate information about the genotyping procedures used, but only 3/51 studies 76, 88, 95 reported that genotype quality control procedures had been adopted. Nine studies 58, 60, 70, 76, 78, 88, 89, 96, 97 clearly specified the number of missing genotypes and six of these provided reasons for the missing data. 58, 60, 70, 76, 78, 96 In the remaining 42/51 studies, it was unclear whether the number contributing to each analysis was equal to the sample size. No study mentioned conducting specific tests for population stratification even though six 57 The relationship between CYP2D6 and drug metabolism was examined in five studies 95, 98, [101] [102] [103] and that between CYP3A5 and drug metabolism in one. 103 Different drugs were studied by each (clozapine, 103 aripiprazole, 101 perphenazine or zuclopenthixol, 102 haloperidol 95 and haloperidol injections 98 ), and no study undertook a comprehensive pharmacokinetic assessment, making it difficult to generalize these findings.
Ten studies were interested in the relationship between efficacy and CYP2D6 [90] [91] [92] [93] [95] [96] [97] [98] [99] or CYP1A2. 94 A wide variety of outcomes were considered across the studies but no two studies measured outcomes in exactly the same way. This made comparisons across studies impossible. Based on the outcomes reported in each study, however, there was a lack of any consistent effect across the studies.
Data on extrapyramidal adverse effects were included in meta-analyses (20/51 studies) ( Table 2) . A significant amount of heterogeneity was found among the Asian studies for TD (see Table 3 ; RevMan forest plot data presented online only) and also to some extent in studies of parkinsonism, akathisia and acute dystonia in Caucasian populations (see RevMan forest plot data presented online only).
The meta-analyses found no significant associations between TD and CYP2D6 (Table 3 ; RevMan forest plot data presented online only) or CYP1A2 (RevMan forest plot data presented online only), either in the Caucasian or Asian populations. Sensitivity analyses confined to prospective studies (Table 4 ; RevMan forest plot data presented online only) only reported a statistically significant association between TD and CYP2D6 when either comparing the mut/ mut genotype to wt/wt (OR ¼ 2.08, 95% confidence interval ¼ 1.21-3.57) or mut/mut þ wt/mut (OR ¼ 1.83, 95% confidence interval ¼ 1.09-3.08). The TD severity as measured by the Abnormal Involuntary Movement Scale was also significantly greater in patients with the CYP2D6 mut/mut genotype compared with the wt/wt genotype (weighted mean difference ¼ 1.80, 95% confidence interval ¼ 0.40-3.19; Table 5 ; RevMan forest plot data presented online only).
Patients with the mut/mut or wt/mut CYP2D6 genotype were significantly more likely to develop parkinsonism than patients with wt/wt (OR ¼ 1.64, 95% confidence interval ¼ 1.04-2.58; RevMan forest plot data presented online only). Most patients with TD or parkinsonism for which significant associations were found were taking typical antipsychotics. No significant associations were found between any genotype and Simpson and Angus scores, which measure the severity of parkinsonism (RevMan forest plot data presented online only).
No significant association was found between having acute dystonia and any of the CYP2D6 genotypes (data presented online only), although the numbers of patients with the mut/mut genotype was small (9/195) . Similarly, the number of patients with akathisia did not significantly differ between patients carrying at least one CYP2D6 mutant allele and those who did (RevMan forest plot data presented online only).
A range of other ADR outcomes (ADRs in general, extrapyramidal symptoms in general, general chronic movement disorders, agranulocytosis, QTc prolongation, weight gain, hyperglycemia and body weight increase) were also measured in a limited number of other studies. As a wide range of CYP450 genes and outcome measures were included in these studies, it is difficult to generalize the findings although no evidence for an association between outcome and genotype was apparent in any individual study with two exceptions in small studies of CYP2D6 that must be treated with extreme caution: a greater proportion of patients with the mut/mut genotype (4/5) experienced general chronic movement disorders than either the wt/wt CYP450 testing for prescribing antipsychotics in adults with schizophrenia N Fleeman et al (18/43) or wt/mut (13/23) genotypes 57 and patients with a wt/mut (5/11) genotype taking olanzapine experienced a statistically significantly larger percentage change in body mass index than patients in the wt/wt group (6/11).
63
CYP1A2 enzyme activity is commonly considered to be affected by smoking; 105 in the current review, only one CYP1A2 study reported pronounced increased effects in terms of Abnormal Involuntary Movement Scale scores in patients who were documented smokers, 60 whereas another four studies 61, 74, 79, 87 failed to report such an association. In addition, a small study 65 of CYP2D6 also reported that differences in Abnormal Involuntary Movement Scale scores between genotype groups were only significant in smokers.
Clinical utility
Out of 1234 papers, only one, 106 available only as a conference presentation (personal communication with Wayne Miles, 14 August 2008) examined clinical utility. In this study, CYP2D6 testing was made available to clinicians in New Zealand prescribing risperidone. From a retrospective review of case notes, and semi-structured interviews with the 42 doctors who had ordered the tests for 93 patients, data on prescribing behavior (change in drug dose) and knowledge about, satisfaction with and perceived knowledge of the test were obtained. Although quotes derived from semi-structured interviews suggest the test assisted with various aspects of dosage, including doctor confidence and changes in dose levels, analysis of risperidone dose in patients at 12 weeks post-baseline produced contradictory results in that no differences between patients with wt/wt genotypes (EMs) and those with mut/mut þ wt/mut (PMs þ IMs) were found.
Discussion
Analytic validity
The sensitivity and specificity of tests reported are excellent, suggesting high analytic validity. However, as with a previous systematic review of antidepressants, 12 very few studies reported on all four aspects of analytic validity, with robustness and quality control in particular commonly neglected. Furthermore, few studies report on the ethnicity of their samples, though most of the CYP2D6 studies were carried out in Europe where Caucasian populations are highly prevalent. This may question the generalizability of such tests in other populations, particularly those Asian populations where, for example, CYP2D6*10 is more prevalent. 107 Notwithstanding these limitations, the studies suggest that genotyping for CYP2D6 and CYP1A2 single nucleotide polymorphisms has high analytic validity.
Clinical validity CYP2D6 is arguably the most important CYP450 gene with regard to the metabolism of antipsychotics, with six typical antipsychotics (thioridazine, perphenazine, fluphenazine, zuclopenthixol, haloperidol and chlorpromazine) and two atypical antipsychotics (risperidone and, to some extent, olanzapine) metabolized by the enzyme encoded by it. 108 Thus, it is not surprising that most of the clinical validity studies also focused on CYP2D6 where some significant associations between TD and parkinsonism and PM genotype. Most patients in the current review were taking typical antipsychotics. Although ORs were statistically significant for some comparisons, which could suggest a clinical argument for testing patients for CYP2D6 to reduce the risk of TD for patients being considered for typical antipsychotic therapy, the differences seen may be considered too small to be clinically meaningful. Very few studies examined the relationship between efficacy and genotype; the small number of studies that did reported contradictory findings. Thus, it is difficult to draw any conclusion about a link between genotype and drug efficacy. A complicating factor that needs to be considered is whether the drug being investigated has an active metabolite(s) produced by the polymorphic pathway, for example, as has been found with risperidone, 109 chlorpromazine and thioridazine. 110 In such situations, efficacy may also depend on the active metabolite, rather than just on the parent compound. Additional issues not considered with efficacy studies are (1) an assessment of adherence to medications, known to be problematic in adults with schizophrenia and (2) variability in the target genes, for example, the dopamine receptors.
Although data from pharmacokinetic studies could not be pooled, the CYP2D6 genotype did affect the pharmacokinetics of drugs where it was the major pathway for elimination. A complicating factor in relation to pharmacokinetic analysis (and therefore with response) with all the CYP450 testing for prescribing antipsychotics in adults with schizophrenia N Fleeman et al antipsychotics is that (1) multiple CYP450 genes are involved in their metabolism, (2) the fractional clearance via CYP2D6 is heavily dependent on the drug being studied; for example it represents a minor pathway for olanzapine and (3) many of the CYP450 genes are prone to interference by either concomitantly administered inducers and inhibitors, which may be drugs or the effect of other influences, such as smoking. A small study 65 of CYP2D6 reported that differences in Abnormal Involuntary Movement Scale between genotype groups were only significant in smokers; CYP2D6 is the only one among the drug metabolizing CYP450 genes, which does not undergo appreciable induction, and therefore genetic variation contributes largely to the interindividual variation in enzyme activity, 111 suggesting that some other effect may be taking place.
The findings of Ellingrod et al. 65 neatly encapsulate the complexity of the problems posed by pharmacogenetic studies in general; while patients were permitted to take any typical antipsychotic in this study, this drug was primarily haloperidol, which is not only metabolized by CYP2D6 but also by CYP1A2 and CYP3A4. Thus, the differences may have occurred not due to metabolism of haloperidol by CYP2D6 but by CYP1A2 or even CYP3A4, reiterating the problems with metabolism highlighted above.
A limitation of the studies undertaken, reflected in the current review, is the wide range of antipsychotics investigated. The lack of effect apparent in many of the studies may therefore have occurred because not all drugs permitted were metabolized by the CYP450 gene being investigated, or because other factors were not taken into account. For example, where patients were on multiple drugs, drug-drug interactions that changed phenocopy may have been important. Other important factors that were typically not evaluated included drug dose, medication adherence and ethnicity.
Another limitation of the current review in terms of CYP2D6 is that alleles were simply classified as wt or mutant, unlike a recent systematic review of CYP2D6 in TD, 11 where the variant alleles were divided into those with null and reduced enzyme activity/function. Although an association between TD and non-functional alleles was detected, there was inconclusive evidence for the reduced function allele, CYP2D6*10. Future studies need to address the effect of heterozygosity, or the carriage of one or two reduced function alleles on the predisposition to the response to antipsychotics efficacy and toxicity). Interestingly, genome-wide association studies of patients enrolled in the CATIE trial of antipsychotic medications 112 has recently failed to find an association between CYP2D6 and schizophrenia, 113 and between CYP2D6 (or indeed any other genetic marker or haplotype association) and TD. 114 This further highlights the complexity of schizophrenia and its treatments and the need to have well-powered studies to disentangle the factors predisposing to the disease from those predisposing to variability in drug response.
The inability to consider UMs separately to EMs could be considered another limitation of the current review. For the purposes for this review, patients with the UM phenotype were classified as wt/wt (that is EM) largely because few individual studies themselves have made the distinction between UMs and EMs, which may in part be due to limitations of the test used for genotyping patients. However, as UMs generally have a lower AUC and thus reduced efficacy at normal doses (or a toxic or exaggerated therapeutic effect where the drug has an active metabolite), including these patients with EMs will clearly dilute any evidence for differences with other genotypes.
Overall, therefore, it is difficult to draw any firm conclusions about the clinical validity of CYP450 testing. This has been compounded by the fact that in patients tested for CYP2D6, very few were known to possess PM or UM phenotypes in the studies included in this review. There is however limited evidence suggesting that there may be associations between genotype and some extrapyramidal adverse effects (namely TD and parkinsonism, as reported in previous reviews 9, 10 and meta-analysis 11 ), particularly for non-EMs. Further study is warranted to assess the link between genotype and clinical utility, particularly in testing for CYP2D6.
Clinical utility
Despite the encouraging results regarding analytic validity, given the lack of compelling evidence from the clinical validity studies, it is disappointing, but not unexpected, that no completed and published studies were found that measured clinical utility. The potential benefit of CYP450 testing is therefore still uncertain and it would be premature to recommend the use of pharmacogenetic testing for adults with schizophrenia. This echoes the finding from a recent systematic review of selective serotonin re-uptake inhibitors in the treatment of non-psychotic depression.
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Implications for future research Studies of analytic validity need to be explicit about patient selection, quality control, assay robustness and the sensitivity and specificity of tests. In studies of clinical validity and clinical utility, there is clearly a need to link phenotype to genotype. As with all drug response phenotypes, such studies will need to be (1) adequately powered to include larger numbers of patients with the PM (and UM) phenotype CYP450 testing for prescribing antipsychotics in adults with schizophrenia N Fleeman et al and (2) incorporate accurate phenotyping with respect to efficacy and toxicity. With respect to the former, validated, widely accepted and robust tools need to used, which will inevitably involve the use of prospective designs rather than the haphazard assessment of efficacy that has occurred through retrospective assessment. In relation to toxicity, many different adverse effects are often grouped, which may be inaccurate as the pathogenesis may vary according to the adverse effect. Again, this highlights the need to recruit patients with individual adverse effects, with an assessment of severity, where possible. Phenotyping for both efficacy and toxicity should also take into account (1) the individual drugs, given that CYP2D6 has a variable role in the metabolism of some antipsychotics (such as risperidone and olanzapine) and (2) confounding factors such as smoking, concomitant medicines, drug dose, medication adherence and ethnicity. Moreover, drug response is a complex phenomenon dependent on a number of genetic factors interacting with environmental factors. Thus, genetic studies should not only encompass the CYP450 isoforms involved in the metabolism of antipsychotics but also the genes encoding targets such as dopamine and 5-HT receptors, and other proteins involved in the mode of action of antipsychotics. Ultimately, there will be a need to mount large multi-center, international studies to assess the effectiveness of multi-marker methods in predicting the response to antipsychotics. Unfortunately, the above research agenda is likely to be costly. However, we believe it is justified given the importance of the disease process, the widespread use of the drugs, the large variation in drug efficacy, the occurrence of many different types of adverse effects, and taken together, the huge economic burden imposed on any economy by the disease and drug use.
